Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is AMGN's Total Equity To Total_Assets?

  Amgen Inc ( AMGN ) |
1989 - 2021 (33 years)

Total Equity To Total_Assets is 
0.16 (1Y -5.84% )

AMGN Stock Price & Total Equity To Total_Assets

Total Equity To Total_Assets for AMGN competitors.
ALXN CELG GILD BIIB GSK BMY JNJ PFE ABBV
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Total Equity To Total_Assets

chevron_right 2021 0.15 -0.8x
( -4.5% / year avg)
chevron_left 1989 0.68
vertical_align_top Peak 0.82 +4.52x
vertical_align_bottom Bottom 0.15
arrow_drop_up # Up Years 17 17 of 33
years up.
arrow_drop_down # Down Years 16
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • AMGN's stock price has rallied +113,400% from $0.22 in 1989 , or -1416.3x faster than it's total equity to total_assets over the same period.
  • If AMGN shrinks it's stock at the same rate as it's total equity to total_assets (-4.5%/year) , it's stock price will shrink +63.1% and hit $155.7 over the next 10 years.
  • AMGN's stock price has gone up 0 of the 17 years (0%) it's total equity to total_assets were also up.
5-Year Change 🚀
+19.8%$26.5BNet Revenue (Sales)
+49.1%$6.4BCost of Revenue (Sales)
+12.8%$20.1BGross Profit Margin
-5.86%3.04Gross Profit Margin Ratio
+12.4%$4.9BResearch and Development (R&D)
+25.2%$7.1BSelling, General, and Administrative (SG&A)
+24.5%$12.1BTotal Operating Expenses
+32.1%$18.5BCost & Expenses
+12.0%$1.3BInterest Expense/Income, Net
+61.1%$3.5BDepreciation & Amortization (D&A)
+11.9%$11.5BEBITDA
-6.63%1.74EBITDA Margin
-1.23%$8.0BOperating Income
-17.6%1.21Operating Margin
-1.88%$7.5BPretax Income (Earnings)
-18.1%1.13Pretax Income (Earnings) Margin
+131%$1.0BProvision For Income Taxes
-10.3%$6.5BNet Income (Earnings)
-25.1%0.97Net Profit Margin
+15.5%11.04Earnings Per Share (EPS)
+16.5%11.04Earnings Per Share (EPS) Diluted
-22.4%$2.3BShares Outstanding
-23.1%$2.3BShares Outstanding (Diluted)
+51.2%$25.1BCash and Cash Equivalents
-83.9%$17.5BShort Term Investments
-66.1%$42.6BCash And Short-Term Investments
+59.9%$15.6BInventory
+21.9%$8.3BOther Current Assets
-45.1%$84.6BTotal Current Assets
+42.5%$66.3BIntangible Assets
+18.3%$125.1BGoodwill and Intangible Assets
-12.1%$251.8BTotal Assets
+47.3%$5.7BAccounts Payables
-96.0%$364.0MShort-term Debt
+34.5%$46.6BTotal Current Liabilities
+12.2%$131.6BLong-term Debt
-38.3%$8.1BOther Non-Current Liabilities
+20.3%$167.5BTotal Non-Current Liabilities
+23.1%$214.2BTotal Liabilities
+3.76%$127.2BCommon Stock
+926%-$85.6BRetained Earnings
+105%-$3.9BAccumulated Other Comprehensive Income Loss
-66.5%$37.6BTotal Shareholders Equity
-12.1%$251.8BTotal Liabilities & Stockholders Equity
+4.53%$131.9BTotal Debt
-2.52%$106.9BNet Debt
-114.6%$208.0MDeferred Income Tax
+312%$1.3BStock-Based Compensation (SBC)
+76.0%-$12.9BChange in Working Capital
+235%-$1.6BAccounts Receivables
-68.2%$38.0BOther Working Capital
+161%-$1.9BOther Non-Cash Items
+4.51%$8.6BNet Cash Provided by Operating Activities
-15.6%-$692.0MInvestments in PP&E
-49.1%-$12.6BPurchase of Investments
-69.0%$8.2BSales/Maturities of Investments
-48.8%-$164.0MOther Investing Activities
+493%-$5.5BNet Cash used for Investing Activities
+1,060%-$5.8BDebt Repayment
+558%-$4.8BCommon Stock Repurchased
+56.4%-$3.7BDividends Paid
-87.0%-$12.0MOther Financing Activities
+294%-$14.4BNet Cash Used Provided by Financing Activities
-407.3%-$11.3BNet Change in Cash
+51.2%$25.1BCash at End of Period
+181%$36.3BCash at Beginning of Period
+4.51%$8.6BOperating Cash Flow
-15.6%-$692.0MCapital Expenditure (capex)
+6.74%$7.9BFree Cash Flow
  • AMGN Historical Total Equity To Total_Assets Table

    Year Total Equity To Total_Assets YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 0.15 -7.9% - -
    4/1/2020 0.16 -10.2% - -
    4/1/2019 0.18 -25.4% - -
    4/1/2018 0.24 -38.6% - -
    4/1/2017 0.39 0.7% - -
    4/1/2016 0.39 2.2% - -
    4/1/2015 0.38 10.9% - -
    4/1/2014 0.35 -7.9% - -
    4/1/2013 0.38 0.0% - -
    4/1/2012 0.37 -31.7% - -
    4/1/2011 0.55 -2.2% - -
    4/1/2010 0.56 2.0% - -
    4/1/2009 0.55 5.1% - -
    4/1/2008 0.52 -3.6% - -
    4/1/2007 0.54 -7.0% - -
    4/1/2006 0.58 -15.7% - -
    4/1/2005 0.69 -6.9% - -
    4/1/2004 0.74 -0.6% - -
    4/1/2003 0.75 13.7% - -
    4/1/2002 0.66 -20.2% - -
    4/1/2001 0.82 5.3% - -
    4/1/2000 0.78 8.3% - -
    4/1/1999 0.72 7.3% - -
    4/1/1998 0.67 -7.3% - -
    4/1/1997 0.73 2.0% - -
    4/1/1996 0.71 9.3% - -
    4/1/1995 0.65 -6.0% - -
    4/1/1994 0.69 0.5% - -
    4/1/1993 0.69 10.7% - -
    4/1/1992 0.62 9.4% - -
    4/1/1991 0.57 -18.8% - -
    4/1/1990 0.7 3.2% - -
    4/1/1989 0.68 - - -

  • About
    Industry: Drug Manufacturers General
    Sector: Healthcare
    Country: US
    IPO Date: 5/1/1987
    Stonk Exchange: NASDAQ
    • Amgen, Inc
    • is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics.
    • The company is headquartered in Thousand Oaks, California and currently employs 21,500 full-time employees.
    • The firm discovers, develops, manufactures and delivers various human therapeutics.
    • The company operates in human therapeutics segment.
    • Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
    • The company focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience.
    • Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
  • Total equity to total assets = Total equity / Total assets


    For more detailed definitions, please see Investopedia.
    Year Total Equity To Total_Assets YoY % Change Stock Price YoY % Change (Stock Price) total se total assets
    4/1/2021 0.15 -7.9% 37636.00 251792.00
    4/1/2020 0.16 -10.2% 40776.00 251024.00
    4/1/2019 0.18 -25.4% 45053.00 249321.00
    4/1/2018 0.24 -38.6% 70119.00 286135.00
    4/1/2017 0.39 0.7% 124463.00 315406.00
    4/1/2016 0.39 2.2% 117671.00 300313.00
    4/1/2015 0.38 10.9% 107735.00 281039.00
    4/1/2014 0.35 -7.9% 94544.00 273438.00
    4/1/2013 0.38 0.0% 80873.00 215621.00
    4/1/2012 0.37 -31.7% 77044.00 205795.00
    4/1/2011 0.55 -2.2% 98095.00 178901.00
    4/1/2010 0.56 2.0% 92247.00 164329.00
    4/1/2009 0.55 5.1% 84571.00 153603.00
    4/1/2008 0.52 -3.6% 75321.00 143826.00
    4/1/2007 0.54 -7.0% 72053.00 132781.00
    4/1/2006 0.58 -15.7% 72402.00 124486.00
    4/1/2005 0.69 -6.9% 78856.00 113811.00
    4/1/2004 0.74 -0.6% 78179.20 105026.90
    4/1/2003 0.75 13.7% 75191.40 100436.10
    4/1/2002 0.66 -20.2% 32712.40 48386.70
    4/1/2001 0.82 5.3% 19090.30 23121.90
    4/1/2000 0.78 8.3% 14329.33 18274.27
    4/1/1999 0.72 7.3% 11288.00 15595.60
    4/1/1998 0.67 -7.3% 8711.70 12922.50
    4/1/1997 0.73 2.0% 8433.10 11584.40
    4/1/1996 0.71 9.3% 7013.30 9845.10
    4/1/1995 0.65 -6.0% 5583.20 8554.80
    4/1/1994 0.69 0.5% 5157.40 7434.20
    4/1/1993 0.69 10.7% 4124.40 5974.00
    4/1/1992 0.62 9.4% 3126.00 5010.80
    4/1/1991 0.57 -18.8% 1471.20 2580.00
    4/1/1990 0.70 3.2% 1092.10 1545.40
    4/1/1989 0.68 654.00 971.07